Skip to main content
. 2020 Sep 4;7(11):ofaa404. doi: 10.1093/ofid/ofaa404

Figure 1.

Figure 1.

Patients from the Quebec HIV Cohort who were eligible for the study. CI, confidence interval; PHW, people with human immunodeficiency virus; PI/r, protease inhibitor/ritonavir; NRTIs, nucleoside reverse-transcriptase inhibitors. *NRTIs = abacavir + lamivudine or tenofovir disoproxil + emtricitabine or tenofovir disoproxil + lamivudine.